Loading clinical trials...

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures

NCT00143143•Pfizer

View on ClinicalTrials.gov

Summary

The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening
•Be currently taking 1 to 3 AEDs.

Exclusion Criteria

•Have a treatable cause of seizures
•Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication

Locations (47)

Pfizer Investigational Site

Innsbruck, Austria

Pfizer Investigational Site

Mauer bei Amstetten, Austria

Pfizer Investigational Site

Sankt Pölten, Austria

Pfizer Investigational Site

Vienna, Austria

Pfizer Investigational Site

Calgary, Alberta, Canada

Pfizer Investigational Site

Edmonton, Alberta, Canada

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Pfizer Investigational Site

Halifax, Nova Scotia, Canada

Pfizer Investigational Site

Barrie, Ontario, Canada

Pfizer Investigational Site

London, Ontario, Canada

Key Dates

Start Date

September 1, 2001

Completion Date

February 1, 2006

Last Updated

July 24, 2006

Enrollment

300

Estimated participants

Conditions

Epilepsies, PartialEpilepsy, Complex Partial

Interventions

Pregabalin

DRUG

Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies

NCT05015868

Epilepsies, PartialEpilepsy Intractable

View study

COMPLETED

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

NCT03054961

Epilepsies, Partial

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Inclusion Criteria

Exclusion Criteria

Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy

Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601